The rapidly changing field of predictive biomarkers of non-small cell lung cancer

被引:2
作者
Toth, Laszlo Jozsef [1 ]
Mokanszki, Attila [1 ]
Mehes, Gabor [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Pathol, Debrecen, Hungary
关键词
NSCLC; driver oncogenes; immune checkpoint inhibitor; gene fusion; biomarker; GROWTH-FACTOR RECEPTOR; MUTATION-SPECIFIC ANTIBODIES; TYROSINE KINASE INHIBITORS; BRAF V600E MUTATION; KRAS G12C MUTATION; PAN-TRK IMMUNOHISTOCHEMISTRY; ANAPLASTIC LYMPHOMA KINASE; ETV6-NTRK3 GENE FUSION; EGFR MUTATIONS; RET PROTOONCOGENE;
D O I
10.3389/pore.2024.1611733
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is a leading cause of cancer-related death worldwide in both men and women, however mortality in the US and EU are recently declining in parallel with the gradual cut of smoking prevalence. Consequently, the relative frequency of adenocarcinoma increased while that of squamous and small cell carcinomas declined. During the last two decades a plethora of targeted drug therapies have appeared for the treatment of metastasizing non-small cell lung carcinomas (NSCLC). Personalized oncology aims to precisely match patients to treatments with the highest potential of success. Extensive research is done to introduce biomarkers which can predict the effectiveness of a specific targeted therapeutic approach. The EGFR signaling pathway includes several sufficient targets for the treatment of human cancers including NSCLC. Lung adenocarcinoma may harbor both activating and resistance mutations of the EGFR gene, and further, mutations of KRAS and BRAF oncogenes. Less frequent but targetable genetic alterations include ALK, ROS1, RET gene rearrangements, and various alterations of MET proto-oncogene. In addition, the importance of anti-tumor immunity and of tumor microenvironment has become evident recently. Accumulation of mutations generally trigger tumor specific immune defense, but immune protection may be upregulated as an aggressive feature. The blockade of immune checkpoints results in potential reactivation of tumor cell killing and induces significant tumor regression in various tumor types, such as lung carcinoma. Therapeutic responses to anti PD1-PD-L1 treatment may correlate with the expression of PD-L1 by tumor cells. Due to the wide range of diagnostic and predictive features in lung cancer a plenty of tests are required from a single small biopsy or cytology specimen, which is challenged by major issues of sample quantity and quality. Thus, the efficacy of biomarker testing should be warranted by standardized policy and optimal material usage. In this review we aim to discuss major targeted therapy-related biomarkers in NSCLC and testing possibilities comprehensively.
引用
收藏
页数:27
相关论文
共 308 条
[1]   The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer [J].
Acquaviva, Jaime ;
Wong, Ricky ;
Charest, Al .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01) :37-52
[2]   Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation [J].
Ambrosini-Spaltro, Andrea ;
Rengucci, Claudia ;
Capelli, Laura ;
Chiadini, Elisa ;
Calistri, Daniele ;
Bennati, Chiara ;
Cravero, Paola ;
Limarzi, Francesco ;
Nosseir, Sofia ;
Panzacchi, Riccardo ;
Valli, Mirca ;
Ulivi, Paola ;
Rossi, Giulio .
CURRENT ONCOLOGY, 2023, 30 (11) :10019-10032
[3]   Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas [J].
Arcila, Maria E. ;
Chaft, Jamie E. ;
Nafa, Khedoudja ;
Roy-Chowdhuri, Sinchita ;
Lau, Christopher ;
Zaidinski, Michael ;
Paik, Paul K. ;
Zakowski, Maureen F. ;
Kris, Mark G. ;
Ladanyi, Marc .
CLINICAL CANCER RESEARCH, 2012, 18 (18) :4910-4918
[4]   Neurotrophin signaling:: many exciting surprises! [J].
Arevalo, J. C. ;
Wu, S. H. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (13) :1523-1537
[5]   Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies [J].
Bahar, Md Entaz ;
Kim, Hyun Joon ;
Kim, Deok Ryong .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[6]   EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies [J].
Bai, Qianming ;
Wang, Jialei ;
Zhou, Xiaoyan .
CANCER TREATMENT REVIEWS, 2023, 120
[7]  
Bailey R., 2003, LUNG CANCER, V41, ps71, DOI DOI 10.1016/S0169-5002(03)91900-3
[8]   SOME BIOLOGICAL PROPERTIES OF 2 NEW AVIAN-SARCOMA VIRUSES [J].
BALDUZZI, PC ;
NOTTER, MFD ;
MORGAN, HR ;
SHIBUYA, M .
JOURNAL OF VIROLOGY, 1981, 40 (01) :268-275
[9]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[10]   THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
NATURE, 1986, 319 (6050) :226-230